[ET Net News Agency, 22 August 2019] Jefferies Research lowered its target price for
Consun Pharmaceutical (01681) to HK$7 from HK$7.6 and maintained its "buy" rating.
The research house said the longer-than-expected restructuring of Yulin business in no
doubt will affect the overall performance of the company in 2019 and 2020. The good news
is two of Consun's product has been included in the latest NRDL (National Reimbursement
Drug List) and one product has just received approval from NMPA (National Medical Products
Administration).
Jefferies believes these three products will become new growth engines for the company
in the next few years.
With the longer than expected restructuring time of Yulin segment, Jefferies lowered
2019/20 revenue forecast by 4.4%/4.5% and gross margin by 3.1ppt/2.5ppt. It also lowered
2019/20 net profit estimates by 10.5%/9.3%. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01681 CONSUN PHARMA
Nominal 
5.480 -0.180 (-3.180%) Others
22/08/2019 13:55
{I-bank focus}Jefferies lowers Consun Pharma (01681) to HK$7
| Remark: | Real time quote last updated: 16/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |